The weight-reducing effect of Axokine—a recombinant form of human CNTF characterized by greater efficacy and specificity—was later confirmed in a population of leptin-resistant patients with obesity, although the clinical trials were discontinued after a significant number of patients developed autoantibodies25. The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.